• Mayo Clinic and Hopkins University， postdoc with Lieping Chen

• Chief Scientist in Major Research Program of the Ministry of Science and Technology

• Vice Chairman of the Synthetic biomedicine Committee of the Chinese Anti-Cancer Association

• CDE- Expert Member of the Review Advisory Committee

• China patent examination technical expert, State Intellectual Property Office

• Previously SVP, MediLink (Suzhou) & CEO, MediLink USA

• Various roles in MNCs, including Pfizer, Genentech, Novartis etc.

• Over fifteen years’ experience in biopharmaceutical research and development: from candidate selection, IND to clinical development

• Expertise in clinical development and translational medicine, including clinical research, clinical operation, and clinical pharmacology in oncology, immunology, and inflammation with both small molecules and biologics

• Excellence Award of doctoral dissertation

• Second prize of National Natural Science Prize

• Postdoc, associate researcher in Institute of Biophysics

• Member of Chinese Academy of Sciences Youth Innovation Promotion Association

• One of the Inventors of PD-1 Ab/IL-X fusion protein

• Main inventor of enhanced CAR-T (BCMA CAR-T secreting PD-1Ab/IL-21 fusion protein)

• Main inventor of “Amplification of anti-tumor CD8+ T cells with PBMCs”

• Postdoc, Stanford University, USA

• Exelixis , Affymax , San Francisco Bay Area

• VP of BIOTECH PHARMA, the first EGFR antibody (Nimotuzumab) discovery and NDA

• COO of THERAPEUTICS, the first tumor neoantigen therapy in China (Neo-T) IND and phase I

• BGI-Research (U.S): Leading the development of antibody platform

• More than 20 years of experience in the development, application and management of small molecule, antibody and CGT